Wolf H, Højgaard K
Lancet. 1983 Jul 16;2(8342):134-6. doi: 10.1016/s0140-6736(83)90117-4.
Of 53 patients with primary bladder tumours of categories T1 or T2 about 50% had concomitant urothelial dysplasia, either carcinoma-insitu or less dedifferentiated dysplasia graded as grade II. In a follow-up study of these patients treated with transurethral resection alone, it was found that new occurrences had developed in 87% of patients with concomitant urothelial dysplasia, compared with 26% of those without dysplasia. Most new occurrences developed within 6 months of initial tumour resection. A new invasive tumour developed in all patients with concomitant carcinoma-in-situ, emphasising the serious prognostic significance of that entity. Thus, urothelial dysplasia concomitant with a bladder tumour is an important determinant factor for future new occurrences.
在53例T1或T2期原发性膀胱肿瘤患者中,约50%伴有尿路上皮发育异常,即原位癌或分级为II级的低分化程度较低的发育异常。在对这些仅接受经尿道切除术治疗的患者进行的一项随访研究中发现,伴有尿路上皮发育异常的患者中有87%出现了新发病变,而无发育异常的患者中这一比例为26%。大多数新发病变在初次肿瘤切除后的6个月内出现。所有伴有原位癌的患者均出现了新的浸润性肿瘤,这凸显了该病变严重的预后意义。因此,膀胱肿瘤伴发的尿路上皮发育异常是未来新发病变的一个重要决定因素。